Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Pathology
Volume 2015, Article ID 380451, 7 pages
http://dx.doi.org/10.1155/2015/380451
Case Report

Isolated Ocular Manifestation of Relapsed Chronic Myelogenous Leukemia Presenting as Myeloid Blast Crisis in a Patient on Imatinib Therapy: A Case Report and Review of the Literature

Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI 48202, USA

Received 29 September 2015; Revised 10 November 2015; Accepted 30 November 2015

Academic Editor: Achille Pich

Copyright © 2015 Rohit Gulati et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. W. Vardiman, N. L. Harris, and R. D. Brunning, “The World Health Organization (WHO) classification of the myeloid neoplasms,” Blood, vol. 100, no. 7, pp. 2292–2302, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Specchia, G. Palumbo, D. Pastore, D. Mininni, A. Mestice, and V. Liso, “Extramedullary blast crisis in chronic myeloid leukemia,” Leukemia Research, vol. 20, no. 11-12, pp. 905–908, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Inverardi, M. Lazzarino, E. Morra et al., “Extramedullary disease in PH'-positive chronic myelogenous leukemia: frequency, clinical features and prognostic significance,” Haematologica, vol. 75, no. 2, pp. 146–148, 1990. View at Google Scholar · View at Scopus
  4. G.-N. Jin, P. Zou, W.-X. Chen, Z.-Y. Ding, and H. Zhou, “Fluorescent in situ hybridization diagnosis of extramedullary nodal blast crisis,” Diagnostic Cytopathology, vol. 41, no. 3, pp. 253–256, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. P. J. Van Dijken, M. Niazi, and R. H. Al-Asiri, “Extramedullary blastic transformation in a child with adult chronic myelocytic leukemia,” Cancer Genetics and Cytogenetics, vol. 76, no. 2, pp. 151–153, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Tsukamoto, S. Ota, C. Ohwada et al., “Extramedullary blast crisis of chronic myelogenous leukemia as an initial presentation,” Leukemia Research Reports, vol. 2, no. 2, pp. 67–69, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. Y.-L. Liu, X. N. Wang, and H. S. Liu, “Differential analysis of BM cell morphology, immunophenotypic, cytogenetic characters and prognosis between myeloblastic and lymphoblastic crisis of CML,” Zhongguo Shi Yan Xue Ye Xue Za Zhi, vol. 22, no. 3, pp. 629–633, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Alegre, E. Ojeda, R. Mataix, and T. Molero, “Ocular infiltration as a presenting form of extramedullary blast crisis in CML,” Sangre, vol. 35, no. 3, pp. 236–237, 1990. View at Google Scholar · View at Scopus
  9. J. H. Lipton, H. D. Mcgowan, and D. G. Payne, “Ocular masquerade syndrome in lymphoid blast crisis of chronic myeloid leukemia,” Leukemia and Lymphoma, vol. 20, no. 1-2, pp. 161–163, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. I. Voican, A. M. Vlădăreanu, H. Bumbea, and M. Begu, “Sudden blast crisis in a chronic myeloid leukemia patient during imatinib therapy,” Romanian Journal of Internal Medicine, vol. 50, no. 3, pp. 241–244, 2012. View at Google Scholar · View at Scopus
  11. Y. Isobe, K. Sugimoto, A. Masuda, Y. Hamano, and K. Oshimi, “Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate,” Internal Medicine Journal, vol. 39, no. 6, pp. 408–411, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Bujassoum, J. Rifkind, and J. H. Lipton, “Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy,” Leukemia and Lymphoma, vol. 45, no. 2, pp. 401–403, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. J. F. Leis, D. E. Stepan, P. T. Curtin et al., “Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571),” Leukemia and Lymphoma, vol. 45, no. 4, pp. 695–698, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Fuchs, M. Reinhöfer, A. Ragoschke-Schumm et al., “Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation,” BMC Blood Disorders, vol. 12, article 9, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. T. K. Saikia, B. Dhabhar, R. S. Iyer et al., “High incidence of meningeal leukemia in lymphoid blast crisis of chronic myelogenous leukemia,” American Journal of Hematology, vol. 43, no. 1, pp. 10–13, 1993. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Thomas, C. K. Stein, T. C. Gentile, and C. M. Shah, “Isolated CNS relapse of CML after bone marrow transplantation,” Leukemia Research, vol. 34, no. 4, pp. e113–e114, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Sharma, J. Grewal, S. Gupta, and P. I. Murray, “Ophthalmic manifestations of acute leukaemias: the ophthalmologist's role,” Eye, vol. 18, no. 7, pp. 663–672, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. M. J. Taylor and P. A. Schuffham, “Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia,” Expert Review of Pharmacoeconomics and Outcomes Research, vol. 9, no. 2, pp. 117–121, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Porkka, P. Koskenvesa, T. Lundán et al., “Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia,” Blood, vol. 112, no. 4, pp. 1005–1012, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Fava, G. Rege-Cambrin, and G. Saglio, “The choice of first-line chronic myelogenous leukemia treatment,” Annals of Hematology, vol. 94, supplement 2, pp. S123–S131, 2015. View at Publisher · View at Google Scholar
  21. S. H. Swerdlow, E. Campo, N. Harris et al., Eds., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC, Lyon, France, 2008.
  22. J. Wei, M. Huang, Y. Wang, and J. Zhou, “Sudden extramedullary blast crisis of chronic myeloid leukemia manifesting as T-Cell lymphoblastic lymphoma,” Onkologie, vol. 36, no. 3, pp. 119–122, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. C. P. Soupir, J.-A. Vergilio, P. Dal Cin et al., “Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis,” American Journal of Clinical Pathology, vol. 127, no. 4, pp. 642–650, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Berger, “Differences between blastic chronic myeloid leukemia and ph-positive acute leukemia,” Leukemia and Lymphoma, vol. 11, supplement 1, pp. 235–237, 1993. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Cuneo, A. Ferrant, J.-L. Michaux et al., “Philadelphia chromosome-positive acute myeloid leukemia: cytoimmunologic and cytogenetic features,” Haematologica, vol. 81, no. 5, pp. 423–427, 1996. View at Google Scholar · View at Scopus
  26. B. Calabretta and D. Perrotti, “The biology of CML blast crisis,” Blood, vol. 103, no. 11, pp. 4010–4022, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. S.-J. Zhang, L.-Y. Ma, Q.-H. Huang et al., “Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 6, pp. 2076–2081, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. C. V. Dang, “MYC on the path to cancer,” Cell, vol. 149, no. 1, pp. 22–35, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. A. A. Zada, J. A. Pulikkan, D. Bararia et al., “Proteomic discovery of Max as a novel interacting partner of C/EBPα: a Myc/Max/Mad link,” Leukemia, vol. 20, no. 12, pp. 2137–2146, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Huang, J. Zheng, J. D. Hu et al., “Discovery of somatic mutations in the progression of chronic myeloid leukemia by whole-exome sequencing,” Genetics and Molecular Research, vol. 13, no. 1, pp. 945–953, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Feo, D. Arcuri, E. Piddini, R. Passantino, and A. Giallongo, “ENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1),” FEBS Letters, vol. 473, no. 1, pp. 47–52, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Sato, “Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia,” Oncogene, vol. 33, no. 42, pp. 5028–5038, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Nakahara, J. Kitaura, T. Uchida et al., “Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells,” Blood, vol. 123, no. 25, pp. 3932–3942, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Bourgne, A. Janel, J. Berger et al., “Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk348) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML),” Leukemia Research, vol. 39, no. 3, pp. 329–334, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. F. El Rassi, J. D. Bergsagel, M. Arellano et al., “Predicting early blast transformation in chronic-phase chronic myeloid leukemia: is immunophenotyping the missing link?” Cancer, vol. 121, no. 6, pp. 872–875, 2015. View at Publisher · View at Google Scholar